Table 1.
Basic characteristics of the seven studies included in the meta-analysis
| Authors & Country | Study design | Sample (M/F) |
Hip (M/F) |
Age (years) |
Diagnostic standard | Disease stage | Follow-up (months) |
|---|---|---|---|---|---|---|---|
| Tian et al., 2023 [22] China | Retrospective cohort study |
T: 17 (NA) C: 24 (NA) |
T: 28 (NA) C: 42 (NA) |
T: 40.8 ± 8.1 C: 42.1 ± 6.4 |
ARCO | II | 14.6 ± 4.8 |
| Liu et al., 2022 [23] China | Retrospective cohort study |
T: 18 (13/5) C: 13 (9/4) |
T: NA C: NA |
T: 36.8 ± 4.8 C: 34.5 ± 6.1 |
Steinberg | II/III/IV | 6 |
| Zhang et al., 2022 [24] China | Retrospective case control study |
T: 30 (19/11) C: 30 (20/10) |
T: NA C: NA |
T: 38.50 ± 10.61 C: 40.63 ± 10.63 |
ARCO | I |
T: 23.40 ± 1.65 C: 23.30 ± 1.66 |
| Li et al., 2022 [25] China | Retrospective cohort study |
T: 50 (36/14) C: 50 (37/13) |
T: NA C: NA |
T: 47.52 ± 12.50 C: 50.68 ± 13.42 |
ARCO | II | 28.53 ± 0.5 |
| Luo et al., 2020 [26] China | Retrospective cohort study |
T: 18 (12/6) C: 22 (12/10) |
T: 26 (NA) C: 29 (NA) |
T: 50.91 ± 7.59 C: 51.39 ± 7.38 |
Ficat | I/II | 6 |
| Luo J et al., 2020 [27] China | Retrospective case control study |
T: 30 (18/12) C: 33 (20/13) |
T: 41 (NA) C: 46 (NA) |
T: 53.00 ± 7.09 C: 50.00 ± 8.84 |
Ficat | I/II | 6 |
| Bi et al., 2019 [28] China | Retrospective case control study |
T: 9 (7/2) C: 11 (8/3) |
T: 16 (NA) C: 20 (NA) |
T: 34.88 ± 3.81 C: 35.30 ± 4.72 |
ARCO | II |
T: 26.8 ± 3.42 C: 26.4 ± 3.65 |
Note: ARCO, Association Research Circulation Osseous; C, Control group; NA, Not available; T, Treatment group